

This application is a continuation-in-part of Application No. 09/368,076, filed August 3, 1999, which is a continuation-in-part of Application Serial No. 09/161,122, filed September 25, 1998, ~~which claims right of priority under 35 U.S.C. § 120 to Application No. 08/316,439, filed September 30, 1994, now U.S. Patent No. 5,840,520, issued November 24, 1998, and~~ which claims priority benefit under 35 U.S.C. § 119(e) of provisional Application Nos. 60/060,153, filed September 26, 1997, 60/084,133, filed May 1, 1998, and 60/089,207, filed June 12, 1998, each of which is incorporated herein by reference in its entirety, and wherein Application Serial No. 09/161,122, filed September 25, 1998 also claims the right of priority under 35 U.S.C. § 120 to Application No. 08/316,439, filed September 30, 1994, now U.S. Patent No. 5,840,520, issued November 24, 1998.

#### IN THE CLAIMS

Please delete claims 1-48 without prejudice.

Please add the following new claims:

49. (new) A vaccine comprising an attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises genetic alterations.

50. (new) The vaccine of claim 49, wherein the genetic alteration is a nucleotide substitution, a nucleotide addition, or a nucleotide deletion.

51. (new) The vaccine of claim 49, wherein the genetic alteration is in a key regulatory domain.

52. (new) The vaccine of claim 49, wherein the genetic alteration is in a key functional domain.

53. (new) The vaccine of claim 49, wherein the virus is capable to go through only one round of replication in the host.